Life Molecular Imaging Receives Orphan Drug Designation for Florbetaben in ATTR Amyloidosis Diagnosis Life Molecular Imaging has been granted orphan drug status by the European Commission for florbetaben (18F), enhancing its role in ATTR amyloidosis diagnosis and treatment.

Life Molecular Imaging Receives Orphan Drug Designation for Florbetaben in ATTR Amyloidosis Diagnosis #Germany #Berlin #Life_Molecular_Imaging #Florbetaben #ATTR_Amyloidosis

European Commission Approves Orphan Drug Status for Florbetaben, Aiding ATTR Amyloidosis Diagnosis Florbetaben (18F) has received orphan drug designation from the European Commission for the diagnosis of ATTR amyloidosis, enhancing early detection and treatment.

European Commission Approves Orphan Drug Status for Florbetaben, Aiding ATTR Amyloidosis Diagnosis #Germany #Berlin #Life_Molecular_Imaging #Florbetaben #ATTR_Amyloidosis

Life Molecular Imaging Receives FDA's Fast Track for [18F]Florbetaben in Cardiac Amyloidosis Diagnosis Life Molecular Imaging announces Fast Track designation from FDA for [18F]Florbetaben, enhancing cardiac AL and ATTR amyloidosis diagnosis.

Life Molecular Imaging Receives FDA's Fast Track for [18F]Florbetaben in Cardiac Amyloidosis Diagnosis #United_States #Boston #FDA_Fast_Track #Life_Molecular_Imaging #Florbetaben